

Amy J Davidoff

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1505313/publications.pdf>

Version: 2024-02-01

136
papers

3,171
citations

172457

29
h-index

175258

52
g-index

138
all docs

138
docs citations

138
times ranked

4235
citing authors

#	ARTICLE	IF	CITATIONS
1	Fine-tuning the cardiac O-GlcNAcylation regulatory enzymes governs the functional and structural phenotype of the diabetic heart. <i>Cardiovascular Research</i> , 2022, 118, 212-225.	3.8	47
2	Practice patterns and real-life outcomes for patients with acute promyelocytic leukemia in the United States. <i>Blood Advances</i> , 2022, 6, 376-385.	5.2	5
3	Telehealth Availability and Use of Related Technologies Among Medicare-Enrolled Cancer Survivors: Cross-sectional Findings From the Onset of the COVID-19 Pandemic. <i>Journal of Medical Internet Research</i> , 2022, 24, e34616.	4.3	13
4	Research on the Economics of Cancer-Related Health Care: An Overview of the Review Literature. <i>Journal of the National Cancer Institute Monographs</i> , 2022, 2022, 12-20.	2.1	7
5	Impact of the COVID-19 Pandemic on Treatment Patterns for Patients With Metastatic Solid Cancer in the United States. <i>Journal of the National Cancer Institute</i> , 2022, 114, 571-578.	6.3	8
6	Patterns of Opioid Prescribing among Medicare Advantage Beneficiaries with Pain and Cardiopulmonary Conditions. <i>Journal of Palliative Medicine</i> , 2021, 24, 195-204.	1.1	3
7	A framework for cancer health economics research. <i>Cancer</i> , 2021, 127, 994-996.	4.1	5
8	Did quality of life for older cancer survivors improve with the turn of the century in the United States?. <i>Journal of Geriatric Oncology</i> , 2021, 12, 102-105.	1.0	1
9	End-of-life patterns of symptom management and cancer-directed care among Medicare beneficiaries with lung cancer: a claims-based analysis. <i>Supportive Care in Cancer</i> , 2021, 29, 3921-3932.	2.2	5
10	Development and evaluation of a proxy for baseline ECOG PS in advanced non-small cell lung cancer, bladder cancer, and melanoma: An electronic health record study. <i>Pharmacoepidemiology and Drug Safety</i> , 2021, 30, 1233-1241.	1.9	1
11	Patterns of medication use at end of life by pediatric inpatients with cancer. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28837.	1.5	1
12	Changes in Multiple Myeloma Treatment Patterns during the Early COVID-19 Pandemic Period. <i>Blood</i> , 2021, 138, 4092-4092.	1.4	0
13	Association of provider experience and clinical outcomes in patients with myelodysplastic syndromes receiving hypomethylating agents. <i>Leukemia and Lymphoma</i> , 2020, 61, 397-408.	1.3	19
14	Patterns of pain medication use associated with reported pain interference in older adults with and without cancer. <i>Supportive Care in Cancer</i> , 2020, 28, 3061-3072.	2.2	9
15	Hypomethylating agent (HMA) therapy use and survival in older adults with Refractory Anemia with Excess Blasts (RAEB) in the United States (USA): a large propensity score-matched population-based study. <i>Leukemia and Lymphoma</i> , 2020, 61, 1178-1187.	1.3	15
16	Patterns of Symptom Management Medication Receipt at End-of-Life Among Medicare Beneficiaries With Lung Cancer. <i>Journal of Pain and Symptom Management</i> , 2020, 59, 767-777.e1.	1.2	13
17	Adoption of Immune Checkpoint Inhibitors and Patterns of Care at the End of Life. <i>JCO Oncology Practice</i> , 2020, 16, e1355-e1370.	2.9	18
18	Clinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United States. <i>Blood Advances</i> , 2020, 4, 2192-2201.	5.2	68

#	ARTICLE	IF	CITATIONS
19	Cost-effectiveness of first-line vs third-line ibrutinib in patients with untreated chronic lymphocytic leukemia. <i>Blood</i> , 2020, 136, 1946-1955.	1.4	32
20	Severe functional limitation due to pain & emotional distress and subsequent receipt of prescription medications among older adults with cancer. <i>Journal of Geriatric Oncology</i> , 2020, 11, 960-968.	1.0	18
21	Patterns of care and clinical outcomes with cytarabine-anthracycline induction chemotherapy for AML patients in the United States. <i>Blood Advances</i> , 2020, 4, 1615-1623.	5.2	32
22	Epidemiology of the classical myeloproliferative neoplasms: The four corners of an expansive and complex map. <i>Blood Reviews</i> , 2020, 42, 100706.	5.7	54
23	Chromosome 1 abnormalities and survival of patients with multiple myeloma in the era of novel agents. <i>Blood Advances</i> , 2020, 4, 2245-2253.	5.2	36
24	The adoption of immune checkpoint inhibitors and patterns of care at the end of life.. <i>Journal of Clinical Oncology</i> , 2020, 38, 12027-12027.	1.6	3
25	The association between initial chemotherapy treatment timing, intensity, and end-of-life (EOL) care trajectory among older adults with advanced stage lung cancer (aLC).. <i>Journal of Clinical Oncology</i> , 2020, 38, e24009-e24009.	1.6	1
26	End-of-life (EOL) trajectories among older adults dying with lung cancer (LC).. <i>Journal of Clinical Oncology</i> , 2020, 38, e24008-e24008.	1.6	0
27	Multiple myeloma (MM) therapy within a Medicare insured patient population: Role of initial care setting and socioeconomic status.. <i>Journal of Clinical Oncology</i> , 2020, 38, e19057-e19057.	1.6	0
28	The impact of clinical trial (CTr) participation on savings performance in the oncology care model (OCM).. <i>Journal of Clinical Oncology</i> , 2020, 38, e19367-e19367.	1.6	0
29	The association between clinical trial (CT) participation, pharmaceutical costs, and savings performance in the Oncology Care Model (OCM).. <i>Journal of Clinical Oncology</i> , 2020, 38, 2-2.	1.6	4
30	Multiple myeloma (MM) therapy within a Medicare-insured patient population: Role of care setting and oncologist sub-specialization in hematologic malignancies.. <i>Journal of Clinical Oncology</i> , 2020, 38, 38-38.	1.6	0
31	Oncologist Sub-Specialization, Care Setting, and Multiple Myeloma Treatment and Outcomes. <i>Blood</i> , 2020, 136, 2-3.	1.4	1
32	Practice Patterns and Real-Life Outcomes for Patients with Acute Promyelocytic Leukemia. <i>Blood</i> , 2020, 136, 21-22.	1.4	1
33	Contemporary Practice Patterns of Tyrosine Kinase Inhibitor Use Among Older Patients with Chronic Myeloid Leukemia in the United States. <i>Blood</i> , 2020, 136, 44-45.	1.4	0
34	Functional trajectories before and after a new cancer diagnosis among community-dwelling older adults. <i>Journal of Geriatric Oncology</i> , 2019, 10, 60-67.	1.0	17
35	Underutilization of guideline-recommended supportive care among older adults with multiple myeloma in the United States. <i>Cancer</i> , 2019, 125, 4084-4095.	4.1	10
36	Temporal patterns and predictors of receiving no active treatment among older patients with acute myeloid leukemia in the United States: A population-level analysis. <i>Cancer</i> , 2019, 125, 4241-4251.	4.1	28

#	ARTICLE	IF	CITATIONS
37	Medical financial hardship among cancer survivors in the United States. <i>Cancer</i> , 2019, 125, 1737-1747.	4.1	108
38	Cancer History, Health Insurance Coverage, and Cost-Related Medication Nonadherence and Medication Cost-Coping Strategies in the United States. <i>Value in Health</i> , 2019, 22, 762-767.	0.3	26
39	Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges. <i>Blood Reviews</i> , 2019, 36, 70-87.	5.7	484
40	Reply to H.J.A. Adams et al. <i>Journal of Clinical Oncology</i> , 2019, 37, 853-854.	1.6	0
41	Epidemiology of myelodysplastic syndromes: Why characterizing the beast is a prerequisite to taming it. <i>Blood Reviews</i> , 2019, 34, 1-15.	5.7	117
42	Clinical Effectiveness of Hypomethylating Agents (HMAs) and Lenalidomide (Len) in Older Patients (pts) with Refractory Anemia with Ring Sideroblasts: A Large Population-Based Study in the United States (US). <i>Blood</i> , 2019, 134, 4748-4748.	1.4	1
43	Impact of an oncology urgent care clinic on emergency department rates.. <i>Journal of Clinical Oncology</i> , 2019, 37, 6615-6615.	1.6	2
44	Chromosome 1 abnormalities and clinical outcomes in multiple myeloma in the era of novel agents.. <i>Journal of Clinical Oncology</i> , 2019, 37, 8044-8044.	1.6	3
45	Affordable Care Act (ACA) Medicaid expansion impact on racial disparities in time to cancer treatment.. <i>Journal of Clinical Oncology</i> , 2019, 37, LBA1-LBA1.	1.6	33
46	Patterns of palliative symptom management (PSM) medication use at end-of-life (EoL) among Medicare beneficiaries with advanced lung cancer (advLC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 130-130.	1.6	1
47	Development and evaluation of a proxy for baseline ECOG PS in advanced non-small cell lung cancer (aNSCLC), bladder cancer (aBCa), and melanoma (aMM): An electronic health records (EHR) study.. <i>Journal of Clinical Oncology</i> , 2019, 37, e18194-e18194.	1.6	1
48	Development and validation of a claims-based approach to proxy ECOG performance status across ten tumor groups. <i>Journal of Comparative Effectiveness Research</i> , 2018, 7, 193-208.	1.4	7
49	Impact of sociodemographic characteristics on underemployment in a longitudinal, nationally representative study of cancer survivors: Evidence for the importance of gender and marital status. <i>Journal of Psychosocial Oncology</i> , 2018, 36, 287-303.	1.2	7
50	Changes in Health Insurance Coverage Associated With the Affordable Care Act Among Adults With and Without a Cancer History. <i>Medical Care</i> , 2018, 56, 220-227.	2.4	42
51	Long-term survival of older patients with MDS treated with HMA therapy without subsequent stem cell transplantation. <i>Blood</i> , 2018, 131, 818-821.	1.4	45
52	Trends in antineoplastic receipt after medicare payment reform: Implications for future oncology payment design. <i>Journal of Cancer Policy</i> , 2018, 17, 51-58.	1.4	2
53	Prescription Drug Coverage and Outcomes of Myeloma Therapy Among Medicare Beneficiaries. <i>Journal of Clinical Oncology</i> , 2018, 36, 2879-2886.	1.6	12
54	Cost-Effectiveness Analysis of Brentuximab Vedotin With Chemotherapy in Newly Diagnosed Stage III and IV Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 3307-3314.	1.6	37

#	ARTICLE	IF	CITATIONS
55	Oncologist volume and outcomes in older adults diagnosed with diffuse large B cell lymphoma. <i>Cancer</i> , 2018, 124, 4211-4220.	4.1	9
56	Counseling patients with higher-risk MDS regarding survival with azacitidine therapy: are we using realistic estimates?. <i>Blood Cancer Journal</i> , 2018, 8, 55.	6.2	26
57	Cost-effectiveness analysis of brentuximab vedotin with chemotherapy in newly diagnosed stage III/IV Hodgkin lymphoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 6609-6609.	1.6	5
58	Undertreated pain: Trends over time for older adults with and without cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 15-15.	1.6	2
59	Cost-related changes in medication use among cancer survivors by socioeconomic status.. <i>Journal of Clinical Oncology</i> , 2018, 36, e18920-e18920.	1.6	0
60	Changes in access to care and financial hardship associated with Affordable Care Act (ACA) implementation for cancer survivors aged 19-64 years.. <i>Journal of Clinical Oncology</i> , 2018, 36, 6565-6565.	1.6	0
61	Cancer survivorship, financial wellbeing and food insecurity in the U.S.. <i>Journal of Clinical Oncology</i> , 2018, 36, 10075-10075.	1.6	0
62	Patterns and determinants of pain and emotional distress in older adults with cancer: A population based study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 10105-10105.	1.6	0
63	Cancer history, health insurance coverage, and cost-related medication nonadherence and medication cost-coping strategies in the United States.. <i>Journal of Clinical Oncology</i> , 2018, 36, 68-68.	1.6	0
64	Association between Oncologist Ownership of Imaging Facilities and Utilization: An Analysis of Positron-Emission Tomography (PET) Use in Lymphoma Settings with Variable PET Utility. <i>Blood</i> , 2018, 132, 3538-3538.	1.4	0
65	Use of Statins, Survival and Incidence of Thrombosis Among Older Adults with Polycythemia Vera: A Population-Based Study. <i>Blood</i> , 2018, 132, 3580-3580.	1.4	2
66	Undertreated emotional distress in older adults with cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 165-165.	1.6	2
67	Do cancer survivors change their prescription drug use for financial reasons? Findings from a nationally representative sample in the United States. <i>Cancer</i> , 2017, 123, 1453-1463.	4.1	65
68	Hypomethylating agent therapy use and survival in older patients with chronic myelomonocytic leukemia in the United States: A large population-based study. <i>Cancer</i> , 2017, 123, 3754-3762.	4.1	18
69	Cost-effectiveness analysis of consolidation with brentuximab vedotin for high-risk Hodgkin lymphoma after autologous stem cell transplantation. <i>Cancer</i> , 2017, 123, 3763-3771.	4.1	25
70	Low-Income Children With Chronic Conditions Face Increased Costs If Shifted From CHIP To Marketplace Plans. <i>Health Affairs</i> , 2017, 36, 616-625.	5.2	8
71	Insights into the role of maladaptive hexosamine biosynthesis and O-GlcNAcylation in development of diabetic cardiac complications. <i>Pharmacological Research</i> , 2017, 116, 45-56.	7.1	51
72	Myelodysplastic Syndromes and Acute Myeloid Leukemia After Radiotherapy for Prostate Cancer: A Population-Based Study. <i>Prostate</i> , 2017, 77, 437-445.	2.3	24

#	ARTICLE	IF	CITATIONS
73	Modest improvement in survival of patients with refractory anemia with excess blasts in the hypomethylating agents era in the United States. <i>Leukemia and Lymphoma</i> , 2017, 58, 982-985.	1.3	16
74	Determinants of Potentially Inappropriate Medication Use among Community-Dwelling Older Adults. <i>Health Services Research</i> , 2017, 52, 1534-1549.	2.0	52
75	Changes in Antiemetic Overuse in Response to Choosing Wisely Recommendations. <i>JAMA Oncology</i> , 2017, 3, 320.	7.1	18
76	Bone Density Screening in Postmenopausal Women With Early-Stage Breast Cancer Treated With Aromatase Inhibitors. <i>Journal of Oncology Practice</i> , 2017, 13, e505-e515.	2.5	12
77	Subsidies for Oral Chemotherapy and Use of Immunomodulatory Drugs Among Medicare Beneficiaries With Myeloma. <i>Journal of Clinical Oncology</i> , 2017, 35, 3306-3314.	1.6	35
78	Health Care Use by Older Adults With Acute Myeloid Leukemia at the End of Life. <i>Journal of Clinical Oncology</i> , 2017, 35, 3417-3424.	1.6	61
79	Risk of myeloid neoplasms after radiotherapy among older women with localized breast cancer: A population-based study. <i>PLoS ONE</i> , 2017, 12, e0184747.	2.5	9
80	Functional trajectories before and after a new cancer diagnosis among community-living older adults.. <i>Journal of Clinical Oncology</i> , 2017, 35, e21547-e21547.	1.6	0
81	Physician volume and discontinuation of rituximab during lymphoma treatment.. <i>Journal of Clinical Oncology</i> , 2017, 35, 6593-6593.	1.6	0
82	Changes in insurance coverage associated with health care reform for cancer survivors aged 19-64 years.. <i>Journal of Clinical Oncology</i> , 2017, 35, 6527-6527.	1.6	0
83	Closure of Medicare Part D coverage gap by the Affordable Care Act (ACA) and use of oral anti-myeloma agents.. <i>Journal of Clinical Oncology</i> , 2017, 35, 6522-6522.	1.6	0
84	Effect of a new cancer diagnosis on labor force participation (LFP): Has there been a change over time?. <i>Journal of Clinical Oncology</i> , 2017, 35, e18004-e18004.	1.6	0
85	Hypomethylating agent (HMA) therapy use and survival in older patients with higher risk myelodysplastic syndromes (HR-MDS) in the United States (USA): A large population-based study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 7057-7057.	1.6	0
86	Disease-related costs of care and survival among Medicare-enrolled patients with myelodysplastic syndromes. <i>Cancer</i> , 2016, 122, 1598-1607.	4.1	19
87	High-Cost, High-Value Oral Specialty Drugs: More Evidence on the Impact of Cost Sharing in Medicare Part D. <i>Journal of Clinical Oncology</i> , 2016, 34, 4307-4309.	1.6	4
88	Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromes. <i>British Journal of Haematology</i> , 2016, 175, 829-840.	2.5	59
89	Associations Between End-of-Life Cancer Care Patterns and Medicare Expenditures. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 1001-1008.	4.9	15
90	Association of 21-gene recurrence score assay and adjuvant chemotherapy use in the medicare population, 2008-2011. <i>Journal of Geriatric Oncology</i> , 2016, 7, 15-23.	1.0	10

#	ARTICLE	IF	CITATIONS
91	Association between Time since Cancer Diagnosis and Health-Related Quality of Life: A Population-Level Analysis. <i>Value in Health</i> , 2016, 19, 631-638.	0.3	30
92	Intensity of end-of-life care for patients with myelodysplastic syndromes: Findings from a large national database. <i>Cancer</i> , 2016, 122, 1209-1215.	4.1	44
93	Cost-Effectiveness Analysis of Consolidation with Brentuximab Vendotin Versus Active Surveillance in Individuals with High-Risk Hodgkin Lymphoma Undergoing High Dose Chemotherapy with Stem Cell Rescue. <i>Blood</i> , 2016, 128, 1188-1188.	1.4	1
94	Early impact of the Affordable Care Act (ACA) on financial worry.. <i>Journal of Clinical Oncology</i> , 2016, 34, 44-44.	1.6	0
95	The benefit of modern cancer therapy for older patients.. <i>Journal of Clinical Oncology</i> , 2016, 34, e18141-e18141.	1.6	0
96	Bone density screening in postmenopausal women with early-stage breast cancer on aromatase inhibitors.. <i>Journal of Clinical Oncology</i> , 2016, 34, 6599-6599.	1.6	0
97	Hypomethylating Agent Therapy and Survival Among Older Patients with Chronic Myelomonocytic Leukemia in the United States: A Large Population-Based Study. <i>Blood</i> , 2016, 128, 394-394.	1.4	0
98	Prevalence of Potentially Inappropriate Medication Use in Older Adults Using the 2012 Beers Criteria. <i>Journal of the American Geriatrics Society</i> , 2015, 63, 486-500.	2.6	127
99	Patient Cost Sharing and Receipt of Erythropoiesis-Stimulating Agents Through Medicare Part D. <i>Journal of Oncology Practice</i> , 2015, 11, e190-e198.	2.5	4
100	Changes in Medication Management After a Diagnosis of Cancer Among Medicare Beneficiaries With Diabetes. <i>Journal of Oncology Practice</i> , 2015, 11, 429-434.	2.5	18
101	The Affordable Care Act and Expanded Insurance Eligibility Among Nonelderly Adult Cancer Survivors. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv181.	6.3	38
102	Variations in erythropoiesis-stimulating agent administration in transfusion-dependent myelodysplastic syndromes impact response. <i>Leukemia Research</i> , 2015, 39, 586-591.	0.8	8
103	Deferasirox therapy is associated with reduced mortality risk in a medicare population with myelodysplastic syndromes. <i>Journal of Comparative Effectiveness Research</i> , 2015, 4, 327-340.	1.4	33
104	Assessing functional status and the survival benefit of chemotherapy for advanced non-small cell lung cancer using administrative claims data. <i>Lung Cancer</i> , 2015, 87, 59-64.	2.0	12
105	Trends in antineoplastic receipt after Medicare payment reform: Implications for future oncology payment design.. <i>Journal of Clinical Oncology</i> , 2015, 33, 6513-6513.	1.6	0
106	Financial hardship associated with cancer in the United States.. <i>Journal of Clinical Oncology</i> , 2015, 33, 6608-6608.	1.6	1
107	Impact of health insurance transitions on cancer survivors and those with no cancer history.. <i>Journal of Clinical Oncology</i> , 2015, 33, 6539-6539.	1.6	0
108	Secondary Myeloid Neoplasms in Older Women with Breast Cancer after Radiotherapy: A Population-Based Study. <i>Blood</i> , 2015, 126, 1676-1676.	1.4	0

#	ARTICLE	IF	CITATIONS
109	Comparative Effectiveness of Azacitidine Versus Decitabine Among Older Adults Diagnosed with Higher-Risk Myelodysplastic Syndromes (HR-MDS). <i>Blood</i> , 2015, 126, 3285-3285.	1.4	1
110	Lack of Association Between Costs of Care and Overall Survival (OS) Among Medicare Beneficiaries with Myelodysplastic Syndromes (MDS) in the United States (US). <i>Blood</i> , 2015, 126, 873-873.	1.4	5
111	Validation of Disability Status, a Claims-based Measure of Functional Status for Cancer Treatment and Outcomes Studies. <i>Medical Care</i> , 2014, 52, 500-510.	2.4	57
112	Use of and spending on supportive care medications among Medicare beneficiaries with cancer. <i>Supportive Care in Cancer</i> , 2014, 22, 2185-2195.	2.2	7
113	Effect of Erythropoiesis-Stimulating Agent Policy Decisions on Off-Label Use in Myelodysplastic Syndromes. <i>Medicare & Medicaid Research Review</i> , 2014, 4, E1-E16.	1.3	8
114	Medical costs and productivity losses of cancer survivors--United States, 2008-2011. <i>Morbidity and Mortality Weekly Report</i> , 2014, 63, 505-10.	15.1	94
115	Out-of-pocket health care expenditure burden for Medicare beneficiaries with cancer. <i>Cancer</i> , 2013, 119, 1257-1265.	4.1	153
116	Patterns of erythropoiesis-stimulating agent use among Medicare beneficiaries with myelodysplastic syndromes and consistency with clinical guidelines. <i>Leukemia Research</i> , 2013, 37, 675-680.	0.8	30
117	A novel approach to improve health status measurement in observational claims-based studies of cancer treatment and outcomes. <i>Journal of Geriatric Oncology</i> , 2013, 4, 157-165.	1.0	121
118	Use and Spending on Antineoplastic Therapy for Medicare Beneficiaries With Cancer. <i>Medical Care</i> , 2013, 51, 351-360.	2.4	13
119	Treatment and outcomes for chronic myelomonocytic leukemia compared to myelodysplastic syndromes in older adults. <i>Haematologica</i> , 2013, 98, 584-590.	3.5	13
120	Impact of Part D on previously uninsured Medicare beneficiaries with hypertension. <i>Journal of Pharmaceutical Health Services Research</i> , 2012, 3, 141-148.	0.6	0
121	Patient and physician characteristics associated with erythropoiesis-stimulating agent use in patients with myelodysplastic syndromes. <i>Haematologica</i> , 2012, 97, 128-132.	3.5	15
122	Simulated Value-Based Insurance Design Applied to Statin Use by Medicare Beneficiaries with Diabetes. <i>Value in Health</i> , 2012, 15, 404-411.	0.3	10
123	Racial differences in presentation, referral and treatment patterns and survival in adult patients with acute myeloid leukemia: A single-institution experience. <i>Leukemia Research</i> , 2012, 36, 140-145.	0.8	33
124	Sociodemographic and patient disparities in use of first-line chemotherapy (CT) in older adult patients (pts) with advanced non-small cell lung cancer (AdvNSCLC): Analysis of Surveillance, Epidemiology, and End Results (SEER)-Medicare data.. <i>Journal of Clinical Oncology</i> , 2012, 30, 6131-6131.	1.6	0
125	How do elderly cancer survivors fare? A comparison of characteristics, health status, health behaviors, and spending between Medicare beneficiaries with and without a cancer history.. <i>Journal of Clinical Oncology</i> , 2012, 30, 6028-6028.	1.6	0
126	Out-of-pocket (OOP) health care expenditure burden for Medicare beneficiaries with cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, 6075-6075.	1.6	0

#	ARTICLE	IF	CITATIONS
127	Did FDA safety warnings and CMS coverage restrictions improve guideline adherence for ESA use for patients with myelodysplastic syndromes?. <i>Journal of Clinical Oncology</i> , 2012, 30, e16519-e16519.	1.6	0
128	Association Between FDA Safety Warnings, CMS Coverage Restrictions and Adherence to Guidelines for ESA Use in Patients with Myelodysplastic Syndromes. <i>Blood</i> , 2012, 120, 971-971.	1.4	0
129	Short Survival and High Rates of Transformation Preval in Chronic Myelomonocytic Leukemia Despite Hypomethylating Agent Therapy.. <i>Blood</i> , 2012, 120, 2800-2800.	1.4	0
130	Chronic Myelomonocytic Leukemia Is Associated with More Frequent and More Rapid Progression to Acute Myeloid Leukemia and Shorter Survival Than Myelodysplastic Syndrome, but Is Less Frequently Treated: Analysis of Surveillance Epidemiology and End Results Data Linked to Medicare Enrollment Claims. <i>Blood</i> , 2011, 118, 2784-2784.	1.4	12
131	Lessons Learned: Who Didn't Enroll In Medicare Drug Coverage In 2006, And Why?. <i>Health Affairs</i> , 2010, 29, 1255-1263.	5.2	18
132	Chemotherapy and Survival Benefit in Elderly Patients With Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 2191-2197.	1.6	271
133	Tertiary Center Referral Patterns for Myelodysplastic Syndrome (MDS) Patients Are Suggestive of Age and Race Disparities. <i>Blood</i> , 2010, 116, 1881-1881.	1.4	0
134	Trends in Disparities in Receipt of Adjuvant Therapy for Elderly Stage III Colon Cancer Patients. <i>Medical Care</i> , 2009, 47, 1229-1236.	2.4	30
135	Effects of Managed Care on Service Use and Access for Publicly Insured Children With Chronic Health Conditions. <i>Pediatrics</i> , 2007, 119, 956-964.	2.1	10
136	Changes in multiple myeloma treatment patterns during the early COVID-19 pandemic period. <i>Leukemia</i> , 0, , .	7.2	4